Press Releases

Gilead Terminates Phase II Clinical Trial of GS 9450 in Patients With Chronic Hepatitis C

FOSTER CITY, Calif., Apr 19, 2010 (BUSINESS WIRE) --Gilead Sciences, Inc. (Nasdaq:GILD) today announced the company is stopping its ongoing Phase II clinical trial of GS 9450, an investigational caspase inhibitor, in patients with chronic hepatitis C. This decision follows reports of significant laboratory abnormalities and adverse events in a number of clinical study participants.

Patient safety is Gilead's top priority, and the company has therefore made the decision to halt this study immediately. Gilead will be conducting a thorough review of all available data to assess future clinical development of the compound.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors that could cause actual results to differ materially from those referred to in the forward-looking statements, including risks that further analysis of the laboratory abnormalities, adverse events and other data obtained to date may not support the continued development of GS 9450. The reader is cautioned not to rely on these forward-looking statements. Gilead directs readers to its Annual Report on Form 10-K for the year ended December 31, 2009. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation Reform Act of 1995 for forward-looking statements. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

For more information on Gilead Sciences, please visit the company's website at or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

SOURCE: Gilead Sciences, Inc.

Gilead Sciences, Inc.
Susan Hubbard, 650-522-5715 (Investors)
Amy Flood, 650-522-5643 (Media)